Pharmaceutical Research and Manufacturers of America v. District of Columbia
United States District Court for the District of Columbia
406 F. Supp.2d 56 (2005)
- Written by Rose VanHofwegen, JD
Facts
The District of Columbia passed the Prescription Drug Excessive Pricing Act of 2005 (PDEPA), prohibiting “any drug manufacturer . . . to sell or supply for sale or impose minimum resale requirements for a patented prescription drug that results in the prescription drug being sold in the district for an excessive price.” The Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Industry Organization (BIO) (plaintiffs) both sued D.C. and multiple officials (defendants), challenging the statute as preempted by federal laws. The trial court consolidated and decided the two lawsuits together.
Rule of Law
Issue
Holding and Reasoning (Leon, J.)
What to do next…
Here's why 806,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,300 briefs, keyed to 988 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.